9 Results for "

irritable bowel syndrome with constipation

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "irritable bowel syndrome with constipation" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-17584
CAS No.: 851199-59-2
Target:  

Guanylate Cyclase

Research Areas:  

Inflammation/Immunology

Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-17584A
CAS No.: 851199-60-5
Target:  

Guanylate Cyclase

Research Areas:  

Cancer

Linaclotide acetate is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
loading...
    loading...
Cat. No.: HY-P3282
CAS No.: 1092457-78-7
Target:  

Guanylate Cyclase

Research Areas:  

Metabolic Disease

MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .
loading...
    loading...
Cat. No.: HY-14147
CAS No.: 112727-80-7
Purity:  98.36%
Synonyms: BRL 24924
Target:  

5-HT Receptor

Research Areas:  

Metabolic Disease

Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .
loading...
    loading...
Cat. No.: HY-17584R
CAS No.: 851199-59-2
Research Areas:  

Cancer

Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
loading...
    loading...
Cat. No.: HY-167687
CAS No.: 1184662-02-9
Synonyms: (RS)-DSP-6952 free base
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

(RS)-Minesapride is a serotonin receptor agonist, exhibiting potential therapeutic activity for patients with irritable bowel syndrome with predominant constipation (IBS-C).
loading...
    loading...
Cat. No.: HY-109065
CAS No.: 1184662-54-1
Synonyms: DSP-6952 free base
Target:  

5-HT Receptor

Research Areas:  

Endocrinology

Minesapride (DSP-6952 free base) is an orally active, selective 5-HT4 receptor partial agonist. Minesapride enhances gastrointestinal motility, colonic transit and defecation function, and inhibits visceral hypersensitivity. Minesapride does not inhibit/induce cytochrome P450 isozymes, has no significant affinity for hERG, and does not trigger the risk of cardiac ischemia via coronary vasoconstriction. Minesapride can be used in research related to constipation-predominant irritable bowel syndrome, chronic constipation, atonic constipation, spastic constipation, functional constipation and functional dyspepsia .
loading...
    loading...
Cat. No.: HY-14147A
Purity:  98.06%
Synonyms: (S)-BRL 24924
Target:  

5-HT Receptor

Research Areas:  

Metabolic Disease

(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study .
loading...
    loading...
Cat. No.: HY-109065A
CAS No.: 1184661-33-3
Synonyms: DSP-6952 hydrobromide
Target:  

5-HT Receptor

Research Areas:  

Endocrinology

Minesapride hydrobromide (DSP-6952 hydrobromide) is an orally active, selective 5-HT4 receptor partial agonist. Minesapride hydrobromide enhances gastrointestinal motility, colonic transit and defecation function, and inhibits visceral hypersensitivity. Minesapride hydrobromide does not inhibit/induce cytochrome P450 isozymes, has no significant affinity for hERG, and does not trigger the risk of cardiac ischemia via coronary vasoconstriction. Minesapride hydrobromide can be used in research related to constipation-predominant irritable bowel syndrome, chronic constipation, atonic constipation, spastic constipation, functional constipation and functional dyspepsia .
loading...
    loading...